Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs
Osama A. Badary
The Pharmacogenomics Journal (2021) Vol. 21, Iss. 3, pp. 275-284
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections
Ren‐Jun Hsu, Wei-Chieh Yu, Guan-Ru Peng, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 103
Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare
Lara Marques, Bárbara Costa, Mariana Pereira, et al.
Pharmaceutics (2024) Vol. 16, Iss. 3, pp. 332-332
Open Access | Times Cited: 61
A review on computer‐aided chemogenomics and drug repositioning for rationalCOVID‐19 drug discovery
Saeid Maghsoudi, Bahareh Taghavi Shahraki, Fatemeh Rameh, et al.
Chemical Biology & Drug Design (2022) Vol. 100, Iss. 5, pp. 699-721
Open Access | Times Cited: 33
Molecular Mechanisms Related to Responses to Oxidative Stress and Antioxidative Therapies in COVID-19: A Systematic Review
Evangelia Eirini Tsermpini, Una Glamočlija, Fulden Ulucan‐Karnak, et al.
Antioxidants (2022) Vol. 11, Iss. 8, pp. 1609-1609
Open Access | Times Cited: 27
Pharmacogenomic Study of SARS-CoV-2 Treatments: Identifying Polymorphisms Associated with Treatment Response in COVID-19 Patients
Alex Serra-Llovich, Natàlia Cullell, Olalla Maroñas, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 553-553
Open Access
Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies
Mohitosh Biswas, Nares Sawajan, Thanyada Rungrotmongkol, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 22
Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions
Sharoen Yu Ming Lim, Basel Al Bishtawi, Willone Lim
European Journal of Drug Metabolism and Pharmacokinetics (2023) Vol. 48, Iss. 3, pp. 221-240
Open Access | Times Cited: 10
Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches
Anna Niarakis, Marek Ostaszewski, Alexander Mazein, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 3
Genetic diversity of variants involved in drug response among Tunisian and Italian populations toward personalized medicine
Haifa Jmel, Stefania Sarno, Cristina Giuliani, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?
Changbo Qu, Gwenny M. Fuhler, Yihang Pan
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5672-5672
Open Access | Times Cited: 22
Bacterial and Fungal Co-Infections and Superinfections in a Cohort of COVID-19 Patients: Real-Life Data from an Italian Third Level Hospital
Manuela Ceccarelli, Andrea Marıno, Sarah Pulvirenti, et al.
Infectious Disease Reports (2022) Vol. 14, Iss. 3, pp. 372-382
Open Access | Times Cited: 14
From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt
Fadya M. Elgarhy, A. Borham, Noha Alziny, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 881-881
Open Access | Times Cited: 2
Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?
Beata Franczyk, Jacek Rysz, Jarosław Miłoński, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 6, pp. 739-739
Open Access | Times Cited: 10
The Potential of Natural Products in the Management of COVID-19
Mona M. Saber, Maha M. Salama, Osama A. Badary
Advances in experimental medicine and biology (2024), pp. 215-235
Closed Access | Times Cited: 1
Autophagy and Mitophagy-Related Pathways at the Crossroads of Genetic Pathways Involved in Familial Sarcoidosis and Host-Pathogen Interactions Induced by Coronaviruses
Yves Pachéco, Dominique Valeyre, Thomas El Jammal, et al.
Cells (2021) Vol. 10, Iss. 8, pp. 1995-1995
Open Access | Times Cited: 12
Thrombocytopenia in COVID‑19 and vaccine‑induced thrombotic thrombocytopenia
Styliani Geronikolou, Işıl Takan, Athanasia Pavlopoulou, et al.
International Journal of Molecular Medicine (2022) Vol. 49, Iss. 3
Open Access | Times Cited: 8
In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir
Qingchen Zhang, Philip W. Melchert, John S. Markowitz
Chemico-Biological Interactions (2022) Vol. 365, pp. 110097-110097
Open Access | Times Cited: 7
Repurposing of drugs targeting the cytokine storm induced by SARS‐CoV‐2
Wern Hann Ng, Patrick Chun Hean Tang, Suresh Mahalingam, et al.
British Journal of Pharmacology (2022) Vol. 180, Iss. 2, pp. 133-143
Open Access | Times Cited: 7
Implications of potential clinically relevant interactions between COVID‐19 vaccines and concomitant medications
Osama A. Badary
Reviews in Medical Virology (2023) Vol. 33, Iss. 3
Closed Access | Times Cited: 3
Nitazoxanide and azithromycin for the early treatment of COVID‐19: A multi‐spectroscopic, biochemical and computational drug–drug interaction study
Syed Abid Ali, Muhammad Abid, Ayaz Ahmed, et al.
Journal of the Chinese Chemical Society (2023) Vol. 70, Iss. 7, pp. 1568-1579
Open Access | Times Cited: 3
Pharmacogenomic Landscape of Covid-19 Therapies From Indian Population Genomes
Soumitra Sahana, Ambily Sivadas, Mohit Mangla, et al.
Pharmacogenomics (2021) Vol. 22, Iss. 10, pp. 603-618
Open Access | Times Cited: 7
Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality
Anmar Al‐Taie, Ayşe Şeyma Büyük, Semra Şardaş
Pulmonary Pharmacology & Therapeutics (2022) Vol. 77, pp. 102172-102172
Open Access | Times Cited: 5
Pharmacogenomics in drug discovery and development
Baldeep Singh, Preeti Jain, K. Devaraja, et al.
Elsevier eBooks (2023), pp. 57-96
Closed Access | Times Cited: 2
Personalized Therapy: Can it Tame the COVID-19 Monster?
Mohd Arish, Farha Naz
Personalized Medicine (2021) Vol. 18, Iss. 6, pp. 583-593
Open Access | Times Cited: 5
The therapeutic landscape for COVID-19 and post-COVID-19 medications from genetic profiling of the Vietnamese population and a predictive model of drug-drug interaction for comorbid COVID-19 patients
Thien Khac Nguyen, Giang Minh Vu, Vinh Chi Duong, et al.
Heliyon (2024) Vol. 10, Iss. 6, pp. e27043-e27043
Open Access
Page 1 - Next Page

Scroll to top